Clinical trials: Colorectal Cancer Recurrent
Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
This phase I trial studies the side effects and the best dose of lenalidomide when given together with cetuximab in treating patients with colorectal cancer or head and neck cancer that has spread to other places in the body and…
- Conditions
- Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
- Trial name
- ADCC (NCT01254617)
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Lenalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Recurrent
Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer
The efficacy and safety of the use of Camrelizumab combined with Apatinib
- Trial name
- NCT04067986
- Testing
- Camrelizumab, Apatinib
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Zhongshan Hospital Xiamen University
Colorectal Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00556413
- Testing
- cetuximab, fluorouracil, irinotecan hydrochloride
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Colorectal Neoplasm
Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities
Positron Emission Tomography (PET scanning) is performed using a total dose of less than 50 mRad per patient visit. Fludeoxyglucose F 18 (FDG) is injected intravenously over 2 min.
- Trial name
- NCT00001568
- Testing
- 2-Fluoro-2-deoxyglucose
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Esophageal Cancer
Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of two different vaccines in treating patients who have cancer of the…
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00012246
- Testing
- carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Colorectal Cancer
Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery
A single arm, prospective, single center Phase1/2 Dietary intervention trial for subjects diagnosed with colorectal cancer and scheduled for tumor resection more than 21 days from informed consent.
- Trial name
- DIET (NCT06349590)
- Testing
- High-fiber/low-fat meals
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Chicago
Colorectal Cancer, Lung Cancer
Lapatinib and Cetuximab in Patients With Solid Tumors
This trial is for patients with colon cancer, head and neck cancer and lung cancer that has not responded to standard therapy. Cetuximab targets a receptor on cancer cells called the Epidermal Growth Factor Receptor or EGFR.
- Conditions
- Colorectal Cancer, Lung Cancer, Head and Neck Cancer
- Trial name
- TYKERB-ITUX 1 (NCT01184482)
- Testing
- cetuximab and lapatinib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Georgetown University
Recurrent Colorectal Carcinoma, Thrombopenia
Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia
This randomized controlled clinical phase II study was designed to compare the effect of rhTPO with rhIL-11 in improving thrombocytopenia in patients with recurrent colorectal cancer who underwent radiotherapy and with…
- Trial name
- NCT03823079
- Testing
- rhTPO, irinotecan, Raltitrexed
- Volunteers
- 50 people
- Sponsor
- Fudan University
Rectal Cancer
1. SAFE-AI ONCO-TRACK: Multimodal GenAI for Early Detection of Minimal Residual Disease and Recurrence in Gastrointestinal Oncology
Current decision tools (TNM, MRI/PET, CEA, and other serum markers, as well as single-marker genomics) are insufficiently predictive of responders, fail to detect early MRD in many cases, and rarely connect molecular biology to…
- Trial name
- ONCO-TRACK (NCT07189520)
- Testing
- Artificial Intelligence
- Volunteers
- 700 people
- Sponsor
- Università Politecnica delle Marche
Locally Advanced Rectal Cancer
Consolidation Versus Induction Chemotherapy in Total Neoadjuvant Therapy of Rectal Cancer With High Risk for Recurrence
The purpose of this study is to identify the most promising treatment sequence in total neoadjuvant therapy for locally advanced rectal cancer with a high risk of recurrence.
- Trial name
- ICONA (NCT05054959)
- Testing
- Consolidation CAPOX Chemotherapy, Induction CAPOX Chemotherapy
- Where
- Slovenia
- Volunteers
- 62 people
- Sponsor
- Institute of Oncology Ljubljana
Colorectal Cancer, Quality of Life
Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can target tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00079066
- Testing
- cetuximab, quality-of-life assessment
- Where
- 33 sites in Australia, Canada
- Volunteers
- 572 people
- Sponsor
- NCIC Clinical Trials Group
Colorectal Cancer
A Multicenter Study on the Safety and Functionality Evaluation of Anastomotic Redo Surgery
To analyze the influencing factors of the success of redo surgery due to anastomotic fistula or anastomotic recurrence after rectal cancer surgery and to evaluate the anal function of patients
- Trial name
- NCT07279961
- Volunteers
- 143 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer, Histiocytic Neoplasm
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer…
- Conditions
- Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
- Trial name
- NCT05786924
- Testing
- S241656, FOLFOX6/FOLFOX7, FOLFIRI
- Where
- 49 sites in United States, Australia and 8 more
- Volunteers
- 554 people
- Sponsor
- Institut de Recherches Internationales Servier
Colorectal Tumors
Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution & Oncologic Outcome
Antibiotic lavage reduces bacterial contamination and decreases SSI infection rate. SSI leads to an immunocompromised situation, leaving unattended the neoplasm.
- Trial name
- NCT02399059
- Testing
- Antibiotic lavage, Normal saline lavage
- Volunteers
- 106 people
- Sponsor
- Hospital General Universitario Elche
Colorectal Cancer, Metastatic Cancer
Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with surgery may kill more tumor cells.
- Trial name
- NCT00006479
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- 111 sites in Australia, Austria and 11 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer
Immediate Compared With Delayed Chemotherapy in Advanced Colorectal Cancer Without Signs or Symptoms of Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002570
- Testing
- fluorouracil, leucovorin calcium
- Where
- 16 sites in United States
- Volunteers
- 67 people
- Sponsor
- NCIC Clinical Trials Group
Metastatic Colorectal Cancer
Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer
The purpose of this study is to determine the efficacy and safety of bevacizumab/capecitabine/oxaliplatin combination in metastatic or recurrent Korean colorectal cancer.
- Trial name
- NCT00378066
- Testing
- Bevacizumab
- Where
- 6 sites in South Korea
- Volunteers
- 49 people
- Sponsor
- Asan Medical Center
Colorectal Cancer
DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic…
- Trial name
- NCT00024401
- Testing
- DHA-paclitaxel
- Where
- 6 sites in United States
- Sponsor
- Theradex
Neoplasm Metastasis
Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.
- Trial name
- NCT02313012
- Testing
- CC-90003
- Where
- 5 sites in United States, Australia
- Volunteers
- 19 people
- Sponsor
- Celgene
Colorectal Cancer
NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of NB1011 in treating patients who have metastatic or…
- Trial name
- NCT00031616
- Testing
- brivudine phosphoramidate
- Where
- 2 sites in United States
- Sponsor
- NewBiotics